• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Healthcare

To Outperform Apple

Intuitive Surgical has done better than Apple in the past six months -- but many investors are still skeptical.
By NICHOLAS VARDY
Feb 15, 2012 | 08:00 AM EST
Stocks quotes in this article: AAPL, ISRG, NOK, RIMM

While recent headlines focused on Apple (AAPL) stock breaking through the magic $500 barrier on Monday, I'd like to turn your attention to another Silicon Valley-based tech stock that penetrated the same magic level -- and on that very same day: Intuitive Surgical (ISRG)

This name became familiar to momentum players in 2011. Still, I found it surprising that the stock has actually outperformed Apple over the past six months -- although Apple has pulled ahead on a shorter-term time frame.

ISRG vs. AAPL -- 2011-2012
Source: Yahoo! Finance
View Chart » View in New Window »

Back at the peak of the dot-com boom in 1999, the field of surgical robotics was little more than a medical curiosity. Today, Intuitive Surgical designs, manufactures, and markets robotic surgical systems under the da Vinci brand that translate the surgeon's natural hand movements into corresponding micro-movements of instruments positioned inside the patient through small puncture incisions. Scarcely a decade out of the technological starting gate, da Vinci is now applied to a wide range of surgical procedures in hospitals in the U.S., including urologic, gynecologic, cardiothoracic, general and head-and-neck surgeries.

Although Intuitive is already a company with $20 billion dollar market capitalization, it still boasts small-cap-like growth numbers. On Jan. 19, the company reported a profit of $3.75 a share, up 24.2% from the year-earlier quarter and well above Thomson Reuters' consensus analyst estimate of $3.35. Sales rose 28% to $497 million vs. consensus of $483.7 million.

The full 2011 results also beat expectations. Revenue climbed 24% to $1.76 billion, compared with the $1.74 billion forecast. Profits hit $12.32 a share, topping expectations of $11.90.

Yet, many investors remain skeptical of Intuitive's recent run. Here's why.

First, the company expects only 2% to 3% of annual revenue growth in system placements this year, down substantially from the approximate 20% growth in 2011. Although that's only a portion of Intuitive's revenue, it does signal a slowdown. Management still forecasts 17%-to-19% total revenue growth this year. However, that's lower than the 24% last year. At the same time, operating income should grow at 39% to 40% of sales, as it has in the last couple of years.

The second reason for skepticism is that Intuitive stock is not cheap. While it happens to trade at the same share price as Apple does, its price-to-earnings ratio of 41.5x is almost triple that of Apple's 14.5x. If the market valued Apple at the same P/E as it did Intuitive, Apple would be a $1,450 stock. Further, given that Apple's top and bottom lines are growing even faster than are those of Intuitive, you can argue that Apple should trade even higher.

So what explains the difference in valuation? I believe it's the fact that Intuitive benefits from a tremendous "moat."

Unlike Apple, Intuitive has no major direct competitors. In addition, there are significant barriers to entry into Intuitive's market. Any new competitor to the da Vinci system would have to completely retrain hospital staff already familiar with Intuitive's system -- and that's not very likely to happen. As a result, the bet is that Intuitive will continue to be successful in expanding the roster of robotic surgical procedures and the number of hospitals in which it will become available in the U.S. and abroad.

That's very different from Apple's situation, as the company operates partially in the same space as does Nokia (NOK) and Research In Motion (RIMM) -- two former tech highflyers that today both have smaller market caps than Intuitive does today.

So is Intuitive a bargain? No, it isn't. But its strong market position means that unlike, say, the Blackberry, it'll be around for while.

_______

Editor's Links

More on Apple:

  • No Skin Off My Apple
  • Catching the Wave: Apple Teetering (Real Money Pro)
  • It's a Bad Time to Short Apple (Real Money Pro)
Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Vardy had no positions in the stocks mentioned.

TAGS: Investing | U.S. Equity | Healthcare | Technology

More from Healthcare

Gilead Sciences Could Retreat Further From Here

Bruce Kamich
Mar 27, 2023 9:25 AM EDT

Share prices peaked in December.

Boston Scientific's Wicked Rally Can Take the Stock 20% Higher

Bruce Kamich
Mar 21, 2023 2:59 PM EDT

BSX has rallied the past nine months.

Why Weakness in Sarepta Therapeutics Is Likely to Continue

Bruce Kamich
Mar 17, 2023 1:20 PM EDT

The trading days between the gaps look like an island surrounded by water.

When Will AbbVie's Long-Term Trend Reassert Itself?

Bruce Kamich
Mar 17, 2023 9:28 AM EDT

Let's drill down on the charts.

3 High Dividend Healthcare Stocks for Passive Income

Bob Ciura
Mar 11, 2023 7:15 AM EST

These recession-resilient names offer above-average dividend yields and decent growth prospects.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 04:00 PM EDT CHRIS VERSACE

    AAP Podcast: This Solar Company Is a Head-Turner

    Listen to my interview with Brian Roth, CEO of sol...
  • 01:56 PM EDT PETER TCHIR

    Very Cautious

    I am very cautious here. I don't like how the c...
  • 08:58 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    How to Adjust Your Trading Style as Market Conditi...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login